CCK receptor polymorphisms: an illustration of emerging themes in pharmacogenomics.
Polymorphisms in G-protein-coupled receptors can alter drug affinity and/or activity. In addition, genetic differences in amino acid sequences can induce ligand-independent signaling, which in turn can lead to disease. With growing efforts in the field of pharmacogenomics, it is anticipated that polymorphism-induced alterations in drug and/or receptor function will be a focus of increasing concern during the course of future drug-development efforts. In this review, the spectrum of pharmacological consequences that result from polymorphisms in the cholecystokinin CCK2 receptor will be discussed, thereby illustrating emerging themes in pharmacogenomics.
Kopin
A S
AS
Department of Medicine and the GRASP Digestive Disease Center, Tupper Research Institute, New England Medical Center, 750 Washington Street, Boston, MA 02111, USA. akopin@msn.com
McBride
E W
EW
Schaffer
K
K
Beinborn
M
M
D000595:Amino Acid Sequence; D000818:Animals; D019204:GTP-Binding Proteins / Q000235:genetics / Q000378:metabolism; D006801:Humans; D008969:Molecular Sequence Data; D011110:Polymorphism, Genetic / Q000235:genetics / Q000502:physiology*; D011949:Receptors, Cholecystokinin / Q000235:genetics / Q000502:physiology*; D013045:Species Specificity
D011949:Receptors, Cholecystokinin; D019204:GTP-Binding Proteins